Clinical Trial Update: TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 trial evaluating TQB2922 plus TAS-102 (trifluridine/tipiracil) with or without bevacizumab in patients with chemotherapy-failed, RAS/BRAF w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• TAS-102 (trifluridine/tipiracil)
• TQB2922

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: RAS/BRAF Wild Type Colorectal Cancer | Phase 1, Phase 2 | Status: RECRUITING